Entrada Therapeutics计划2026年底前启动ENTR-601-50全球1/2期临床研究

美股速递
Jan 08

生物技术公司Entrada Therapeutics宣布,预计将在2026年年底前启动其候选药物ENTR-601-50的全球性1/2期多次给药(MAD)临床研究。这一时间表标志着该公司在推进其研发管线方面迈出了关键一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10